Home › Urothelial (Transitional Cell) Carcinoma › Virginia › Charlottesville
Urothelial (Transitional Cell) Carcinoma clinical trials in Charlottesville, VA
5 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Charlottesville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #66, Charlottesville
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RecruitingPhase 3
- University of Virginia Comprehensive Cancer Center, Charlottesville
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
RecruitingPhase 1
- The University of Virgina, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Charlottesville
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Virginia, Charlottesville
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
Other studies in Charlottesville
- Non-Small Cell Lung Cancer21 studies
- Acute Myeloid Leukemia16 studies
- Prostate Cancer15 studies
- Metastatic Cancer13 studies
- Endometrial Cancer13 studies
- Cancer (all types)13 studies
- Lung Cancer13 studies
- Heart Failure11 studies
- Ovarian Cancer10 studies
- Colorectal Cancer10 studies
- Type 1 Diabetes9 studies
- Breast Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.